Another set of extrapolations - just interesting for perspective on future value:
AMGEN's first-year revenues for their BLINCYTO drug for treating ALL was USD $77M (2015 revenue)
AML is 3.2x the incidence of ALL, so extrapolating, first-year revenue from Bisantrene would be in the order of USD $246M
Cinuvel (CUV) revenue for 2019 was AUD $31M, their market cap is currently AUD $1.28B
CUV revenue to market cap multiple is 41.3x
So 41.3x estimated first year sales for Bisantrene would imply a Market Cap of AUD $14.66B if RACE Oncology took Bisantrene through to production and sales.
Looking at Revenue growth .... it's revenue growth of BioTechs that drive high market caps when they are generating revenues.
BLINCYTO revenues grew at an average 46% per year for 5 years (this is actual growth of AMGEN's BLINCYTO revenues). Extraordinary!
More conservative view would be ramping up to peak revenues over 7years but at a slower rate. This is from one of the research notes on PAR:
RAC Price at posting:
73.0¢ Sentiment: Buy Disclosure: Held
